Company Overview and News

0
Velpic enters trading halt ahead of news release

2018-07-20 proactiveinvestors.com.au
Velpic Ltd (ASX:VPC) has been granted a trading halt by the ASX pending the release of an update on the proposed disposal of part of the company’s business which will require the approval of shareholders.
VPC

0
Velpic disposes of e-learning business for estimated $2.4 million

2018-07-13 proactiveinvestors.com.au
Velpic Ltd (ASX:VPC) has agreed to sell the customer book of its learning management system (LMS) business to an existing partner, GO1 Pty Ltd.
VPC

0
Velpic prepares to dispose part of its business

2018-07-10 proactiveinvestors.com.au
Velpic Ltd (ASX:VPC) has been granted a trading halt by the ASX pending the release of information regarding a proposed disposal of part of the company’s business.
VPC

0
Velpic has strongest quarter of revenue growth yet

2018-04-08 proactiveinvestors.com.au
Velpic Ltd (ASX:VPC) has had a strong quarter of revenue growth across its learning management system (LMS).
VPC

0
Velpic appoints globally experienced Justin Klintberg to board to assist in next growth phase

2018-04-02 proactiveinvestors.com.au
Velpic Ltd (ASX:VPC) has appointed Justin Klintberg to the board of directors following the resignations of Harry Karelis and Daniel Rohr.
VPC

35
Velpic and NowForce collaborate to address global security issues

2018-03-22 proactiveinvestors.com.au
Velpic Ltd (ASX:VPC) was active on all fronts in 2017, and there is early evidence in 2018 that the initiatives undertaken by the group are starting to pay dividends.
GJV VPC AAI NWS NWSA COF AA.PR MALRY AA.PRB MALRF MIN AA

0
Velpic secures first client from NowForce partnership in ASX-listed Threat Protect

2018-03-21 proactiveinvestors.com.au
Velpic Ltd (ASX:VPC) has secured its first client under its reseller agreement related to the NowForce platform in Threat Protect (ASX:TPS).
TPS VPC

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

Silicon Investor Message Boards

This table lists all message boards related to ASX:VPC / VELPIC LIMITED on message board site Silicon Investor.

Valkyries Petroleum (VPC)